Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C34H38F2N6O2 |
| Molecular Weight | 600.7013 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
FC1=C(F)C=C(CNC2=C3C=CC(NC(=O)CCN4CCCC4)=CC3=NC5=C2C=CC(NC(=O)CCN6CCCC6)=C5)C=C1
InChI
InChIKey=NGMQRZIFCCYTRG-UHFFFAOYSA-N
InChI=1S/C34H38F2N6O2/c35-28-10-5-23(19-29(28)36)22-37-34-26-8-6-24(38-32(43)11-17-41-13-1-2-14-41)20-30(26)40-31-21-25(7-9-27(31)34)39-33(44)12-18-42-15-3-4-16-42/h5-10,19-21H,1-4,11-18,22H2,(H,37,40)(H,38,43)(H,39,44)
| Molecular Formula | C34H38F2N6O2 |
| Molecular Weight | 600.7013 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 11:32:11 UTC 2023
by
admin
on
Sat Dec 16 11:32:11 UTC 2023
|
| Record UNII |
6H8FDD5016
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
6H8FDD5016
Created by
admin on Sat Dec 16 11:32:11 UTC 2023 , Edited by admin on Sat Dec 16 11:32:11 UTC 2023
|
PRIMARY | |||
|
11570708
Created by
admin on Sat Dec 16 11:32:11 UTC 2023 , Edited by admin on Sat Dec 16 11:32:11 UTC 2023
|
PRIMARY | |||
|
1173659-25-0
Created by
admin on Sat Dec 16 11:32:11 UTC 2023 , Edited by admin on Sat Dec 16 11:32:11 UTC 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> INHIBITOR |
One compound is a trisubstituted acridine compound AS1410, a close analogue of BRACO-19. Synergistic behaviour was observed in both cell lines (MCF7 and A549) with both compounds in combination with cis-platin, but only when the ratio of AS1410:cis-platin is >1. In vivo tumour xenograft studies with the A549 lung cancer model and the trisubstituted acridine compound AS1410 showed only a modest anti-tumour effect when administered alone, but produced rapid and highly significant decreases in tumour volume when administered in combination with cis-platin.
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
Developer: Antisoma, Cancer Research UK; Mechanism of Action: Telomerase inhibitor
Highest Development Phase: Discontinued for Cancer; Most Recent Events: 09 Dec 2005 Antisoma has decided not to advance AS 1410 to clinical development due to unacceptable toxicity, 03 Jun 2005 Antisoma has signed an agreement with Heraeus so that the latter company will provide supplies of AS 1410 for clinical trials, 05 May 2005 Data presented at the 96th Annual Meeting of the American Association for Cancer Research (AACR-2005) have been added to the Cancer pharmacodynamics section
|
